Oncternal Therapeutics, Inc. (GTXI) [Rocket]

Overview

Oncternal Therapeutics, Inc. (GTXI)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/06/2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
10/04/2023	4	Leavitt Chase C. (General Counsel/Secretary) has filed a Form 4 on Oncternal Therapeutics, Inc.
10/04/2023	4	Yazji Salim (Chief Medical Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.
10/04/2023	4	BREITMEYER JAMES B (CEO) has filed a Form 4 on Oncternal Therapeutics, Inc.
10/04/2023	4	VINCENT RICHARD G (CFO) has filed a Form 4 on Oncternal Therapeutics, Inc.
10/04/2023	4	Krishnan Rajesh (Chief Technical Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.
08/10/2023	10-Q	Quarterly Report for the period ended June 30, 2023

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16
Revenues	33.0	4.3	24.1	3.4	2.4	2.5	0.0	0.0
Revenue growth	36.9%	27.9%		39.2%	-3.8%
Cost of goods sold	46.4	0.0	35.7	0.0	0.0	0.0	0.0	0.0
Gross profit	-13.5	4.3	-11.6	3.4	2.4	2.5	0.0	0.0
Gross margin	-40.8%	100.0%	-48.1%	100.0%	100.0%	100.0%
Selling, general and administrative
Research and development		24.1		12.5	10.2	8.3	21.5	17.2
General and administrative	13.5	11.6	11.6	8.4	7.3	1.8	9.2	8.7
EBIT	-44.9	-31.4	-31.4	-17.5	-15.0	-7.6	-30.7	-25.9
EBIT margin	-136.3%	-726.9%	-130.2%	-519.8%	-619.4%	-300.9%
Pre-tax income	-44.2	-31.3	-31.3	-17.2	-34.2	-6.6	-30.4	-17.7
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-44.2	-31.3	-31.3	-17.2	-34.2	-6.6	-30.4	-17.7
Net margin	-133.9%	-726.1%	-130.1%	-510.4%	-1409.8%	-261.0%

Diluted EPS	($0.84)	($0.64)	($0.64)	($0.85)	($3.31)	($1.83)	($1.75)	($1.22)
Shares outstanding (diluted)	52.6	49.3	49.3	20.3	10.3	3.6	17.4	14.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.